IP Library › Granted Patent US 9,782,377
Granted Patent B2
US 9,782,377 · App. 10/546,158 · Granted Oct 10, 2017

Composition for normalization of infradian rhythm

Inventors: Kengo Akimoto (Kawasaki, JP); Yoshiko Ono (Osaka, JP); Hiroshi Kawashima (Takatsuki, JP); Katsuya Nagai (Minoo, JP)
Assignee: SUNTORY HOLDINGS LIMITED
A61K31/202A23L33/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,782,377
App. No.
10/546,158
Granted
Oct 10, 2017
Kind
B2
Abstract

A composition having a normalizing action for infradian rhythm and/or a synchronization promoting action for circadian rhythm (biological clock) containing arachidonic acid and/or an arachidonic acid-containing compound.

Claims (33)

1. A method of treating a patient requiring a normalizing action for infradian rhythm and/or a synchronization promoting action for circadian rhythm (biological clock) comprising:

administering a composition containing an arachidonic acid-containing compound to a patient in need thereof in an arachidonic acid amount of 0.1 to 2 g per day,

wherein the arachidonic acid-containing compound is an alcohol ester of arachidonic acid or triglyceride or glycolipid comprising arachidonic acid as a part of or all of the constituting fatty acids.

2. The method according to claim 1 , wherein the triglyceride comprising arachidonic acid as all of or a part of the constituting fatty acids is a triglyceride where medium-chain fatty acids are bonded to 1,3-positions and arachidonic acid is bonded to 2-position.

3. The method according to claim 2 , wherein the medium-chain fatty acid is selected from fatty acids having 6 to 12 carbons.

4. The method according to claim 3 , wherein the medium-chain fatty acid is selected from fatty acids having 8 carbons.

5. A method of treating a patient requiring a normalizing action of infradian rhythm and/or a synchronization promoting action for circadian rhythm (biological clock) comprising:

administering a composition containing a triglyceride comprising arachidonic acid as all of or a part of a constituting fatty acids to a patient in need thereof.

6. The method according to claim 5 , wherein the ratio of arachidonic acid of the triglycerides containing a triglyceride comprising arachidonic acid as all of or a part of the constituting fatty acids is not less than 10% by weight to total fatty acids which constitute the triglyceride.

7. The method according to claim 5 , wherein the triglyceride comprising arachidonic acid as all of or a part of the constituting fatty acids is extracted from a microorganism belonging to genus Mortierella.

8. The method according to claim 5 , wherein the triglyceride comprising arachidonic acid as all of or a part of the constituting fatty acids is a triglyceride which does not contain eicosapentaenoic acid or, even if contained, its amount is not more than 1%.

9. A method of treating a patient requiring a normalizing action of infradian rhythm and/or a synchronization promoting action for circadian rhythm (biological clock) comprising:

administering a composition containing triglycerides to a patient in need thereof, wherein the triglycerides contain not less than 5 mol % of a triglyceride having a medium-chain fatty acids bonded to 1,3-positions and arachidonic acid bonded to 2-position, and wherein the composition is administered in an arachidonic acid amount of 0.1 to 2 g per day.

10. The method according to claim 9 , wherein the medium-chain fatty acid is selected from fatty acids having 6 to 12 carbons.

11. The method according to claim 10 , wherein the medium-chain fatty acid is selected from fatty acids having 8 carbons.

12. A method according to claim 1 , wherein said administering alleviates in said patient a biorhythm disorder caused by abnormality of infradian rhythm.

13. The method according to claim 12 , wherein the composition is administered in an amount effective to alleviate a biorhythm disorder, wherein the biorhythm disorder is a sleep disorder.

14. The method according to claim 12 , wherein the composition alleviates a biorhythm disorder caused by retardation of synchronization of circadian rhythm (biological clock).

15. The method according to claim 14 , wherein the biorhythm disorder is jet lag, headache, tinnitus, palpitation, nausea, gastralgia, diarrhea or lowering in ability of judgment and concentration.

16. The method according to claim 12 , wherein the biorhythm disorder is delayed sleep phase syndrome.

17. The method according to claim 1 , wherein the composition is a food composition or a pharmaceutical composition.

18. The method according to claim 17 , wherein the arachidonic acid-containing compound is an alcohol ester of arachidonic acid, or triglyceride or glycolipid containing arachidonic acid as a part of or all of the constituting fatty acid.

19. The method according to claim 18 , wherein the triglyceride comprising arachidonic acid as all of or a part of the constituting fatty acids is a triglyceride where a medium-chain fatty acids are bonded to 1,3-positions and arachidonic acid is bonded to 2-position.

20. The method according to claim 19 , wherein the medium-chain fatty acid is selected from fatty acids having 6 to 12 carbons.

21. The method according to claim 20 , wherein the medium-chain fatty acid is selected from fatty acids having 8 carbons.

22. The method according to claim 1 , wherein the composition contains not less than 0.001% by weight of a triglyceride in which a medium-chain fatty acid is bonded to 1,3-positions and arachidonic acid is bonded to 2-position.

23. The method according to claim 22 , wherein the medium-chain fatty acid is selected from fatty acids having 6 to 12 carbons.

24. The method according to claim 23 , wherein the medium-chain fatty acid is selected from fatty acids having 8 carbons.

25. The method according to claim 17 , wherein the food composition is a functional food, a nutritional supplement, a designated health food or a geriatric food.

26. A method of treating a patient requiring a normalizing action for infradian rhythm and/or a synchronization promoting action for circadian rhythm (biological clock) comprising:

administering a composition containing a single active ingredient to a patient in need thereof,

wherein the single active ingredient consists of an arachidonic acid-containing compound,

wherein the arachidonic acid-containing compound is an alcohol ester of arachidonic acid or triglyceride or glycolipid comprising arachidonic acid as a part of or all of the constituting fatty acids, and wherein the composition is administered in an arachidonic acid amount of 0.1 to 2 g per day.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2009
From: SUNTORY LIMITED
To: SUNTORY HOLDINGS LIMITED
Reel/Frame 023049/0707 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2005
From: AKIMOTO, KENGO; ONO, YOSHIKO; KAWASHIMA, HIROSHI; NAGAI, KATSUYA
To: SUNTORY LIMITED
Reel/Frame 017483/0031 →
Priority Claims (1)
JP 2003-088956 · Mar 27, 2003 · national
Continuity (1)
Related Publication 20060073187A1 · Apr 6, 2006